s. Provisions, contingent liabilities and contingent assets
Provisions are recognised when present obligations as a result of past events will probably lead to an outflow of economic resources from the Company and they can be estimated reliably. Timing or amount of the outflow may still be uncertain. A present obligation arises from the presence of a legal or constructive obligation that has resulted from past events.
Provisions are measured at the best estimate of expenditure required to settle the present obligation at the reporting date, based on the most reliable evidence, including the risks and uncertainties associated with the present obligation.
In those cases where the possible outflow of economic resource as a result of present obligations is considered improbable or remote, or the amount to be provided for cannot be measured reliably, no liability is recognised in the balance sheet.
Contingent liabilities are disclosed when there is a possible obligation arising from past events, the existence of which will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the Company or a present obligation that arises from past events where it is either not probable that an outflow of resources will be required to settle the obligation or a reliable estimate of the amount cannot be made. The Company does recognise a contingent liability but discloses its existence in the financial statements.
Any amount that the Company can be virtually certain to collect from a third party with respect to the obligation is recognised as a separate asset up to the amount of the related provisions. All provisions are reviewed at each reporting date and adjusted to reflect the current best estimate.
Contingent assets are not recognized in the financial statements.
t. Exceptional Items
An item of income or expense which by its size, type or incidence requires disclosure in order to improve an understanding of the performance of the Company is treated as an exceptional item and the same is disclosed in standalone statement of profit and loss and in the notes forming part of the standalone financial statements.
1.4 Critical management judgments in applying accounting policies and estimation uncertainty
The preparation of the Company's financial statements requires management to make judgments, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities and the related disclosures.
Judgments
Research and developments costs: Management monitors progress of internal research and development projects by using a project management system. Significant judgment is required in distinguishing research from the development phase. Development costs are recognised as an asset when all the criteria are met, whereas research costs are expensed as incurred. Management also monitors whether the recognition requirements for development costs continue to be met. This is necessary due to inherent uncertainty in the economic success of any product development.
Recognition of deferred tax assets: The extent to which deferred tax assets can be recognized is based on an assessment of the probability of the future taxable income against which the deferred tax assets can be utilised.
Provisions, contingent liabilities and contingent assets: The Company is the subject of legal proceedings and tax issues covering a range of matters, which are pending in various jurisdictions. In view of the uncertainty inherent in such matters, it is difficult to
predict the final outcome of such matters. The cases and claims against the Company often raise difficult and complex factual and legal issues, which are subject to many uncertainties, including but not limited to the facts and circumstances of each particular case and claim, the jurisdiction and the differences in applicable law. In the normal course of business, management consults with legal counsel and certain other experts on matters related to litigation and taxes. The Company accrues a liability when it is determined that an adverse outcome is probable and the amount of the loss can be reasonably estimated.
Impairment of financial assets: At each balance sheet date, based on historical default rates observed over expected life, the management assesses the expected credit loss on outstanding financial assets.
Evaluation of indicators for impairment of assets: The evaluation of applicability of indicators of impairment of assets requires assessment of several external and internal factors which could result in deterioration of recoverable amount of the assets.
Estimates
Useful lives of depreciable / amortisable assets: Management reviews its estimate of the useful lives of depreciable/amortisable assets at each reporting date, based on the expected utility of the assets. Uncertainties in these estimates relate to technical and economic obsolescence that may change the utility of certain software, IT equipment and other plant and equipment.
Defined benefit obligation: Management's estimate of the Defined Benefit Obligations (DBO) is based on a number of critical underlying assumptions such as standard rates of inflation, mortality, discount rate and anticipation of future salary increases. Variation in these assumptions may significantly impact the DBO amount and the annual defined benefit expenses.
Fair value measurements
Management applies valuation techniques to determine the fair value of financial instruments (where active market quotes are not available). This involves developing estimates and assumptions consistent with how market participants would price the instrument.
1.5 New and amended standards
The Company has applied the following amendments for the first time for their annual reporting period commencing 1 April 2023:
Ind AS 8 - Accounting Policies, Changes in Accounting Estimates and Errors: The amendments to Ind AS 8 clarify the distinction between changes in accounting estimates, changes in accounting policies and the correction of errors. They also clarify how entities use measurement techniques and inputs to develop accounting estimates. The amendments had no impact on the Company's standalone financial statements.
Ind AS 1 - Presentation of Financial Statements: The amendments to Ind AS 1 provide guidance on applying materiality judgements to accounting policy disclosures. The amendments aim to help entities provide accounting policy disclosures that are more useful by replacing the requirement for entities to disclose their 'significant' accounting policies with a requirement to disclose their 'material' accounting policies and adding guidance on how entities apply the concept of materiality in making decisions about accounting policy disclosures.
The amendments have had an impact on the Company's disclosures of accounting policies, but not on the measurement, recognition or presentation of any items in the Company's financial statements.
Ind AS 12 - Income Taxes: The amendments to Ind AS 12 Income Tax narrow the scope of the initial recognition exception, so that it no longer applies to transactions that give rise to equal taxable and deductible temporary differences such as leases. The above amendments did not have any material impact on the amounts recognised in prior periods and are not expected to significantly affect the current or future periods.
1.6 Recent accounting pronouncements:
Ministry of Corporate Affairs ("MCA") notifies new standards or amendments to the existing standards under Companies (Indian Accounting Standards) Rules as issued from time to time. MCA has issued following amendments:
Amendment to Ind AS 1 'Presentation of Financial Statements'- Classification of Liabilities as current or non-current and non¬ current liabilities with covenants. The amendment includes specific provisions that will take effect for reporting periods beginning on or after April 01,2026, retrospectively, as outlined below:
(i) Breach of material covenant for long-term loan arrangement on or before the end of reporting period with the effect that liability becomes payable on demand as on reporting date, then it shall be classified as current liability, if lender agreed after reporting period and before approval of standalone financial statements to not demand payment as a consequence of breach.
(ii) Classify as non-current liability, if lender agreed by the end of reporting period to provide grace period ending at least 12 months after reporting period within which entity can rectify the breach provided lender does not demand immediate repayment.
(iii) Disclose information about the timing of settlement to understand the impact of the liability on the standalone financial statements.
The Company does not expect this amendment to have an impact on its operations or standalone financial statements.
(i) Refer note 37(B) for information on contractual commitments related to property, plant and equipment.
(ii) During financial year ended March 31, 2025, the Company has classified its properties amounting ?35.00 million (Gross value ?40.80 million and accumulated depreciation ?5.80 million) as investment property from property plant and equipment, due to change in plan and objective towards utilisation of said properties.
(iii) During financial year ended March 31, 2026, the Company has classified its properties amounting ?13.45 million (Gross value ?16.99 million and accumulated depreciation ?3.54 million) as investment property from property, plant and equipment, due to change in plan and objective towards utilisation of said properties.
(iv) The Company carried out an impairment assessment of the cash-generating unit (CGUs) in terms of Ind AS 36 "Impairment of Assets" using a discounted cash flow model which is based on the net present value of the forecasted earnings of the CGUs with the help of an external valuation specialist. This is calculated using certain assumptions viz. discount rate of 13.78%, terminal year growth rate of 4% and cash flow forecasts for 5 years. The Company has also involved independent, registered valuer to assess the value in use of the CGUs by cash flow approach. These forecasts contain management's best view of the expected performance of the CGU based on the management's knowledge of the market environment, strategic initiatives and future business plans. As per the management's assessment, there is no impairment required to be recognized in the statement of profit and loss account.
(v) The Company has not revalued its property, plant and equipment during the financial year 2025-26 and 2024-25.
(vi) The Company has adopted cost model for its property, plant and equipment.
(b) Terms / rights attached to equity shares:
The Company has only one class of equity shares having a par value of ?1 per share. Each holder of equity shares is entitled to one vote per share. The Company declares and pays dividends in Indian Rupees. The dividend if any, proposed by the Board of Directors is subject to the approval of the shareholders in the ensuing Annual General Meeting. The Board of Directors has not proposed any dividend on equity shares for current year and previous year.
In the event of liquidation of the Company, the holders of equity shares will be entitled to receive remaining assets of the Company, after distribution of all preferential amounts including preference shares. The distribution will be in proportion to the number of equity shares held by the equity shareholders.
The Company has not reserved any shares for issuance under options.
Notes:
i) Includes income tax demand of ?99.52 million in respect to Assessment Year 2005-06. The Income Tax Department had issued alleged demand based on certain grounds related to purchases made by the Company from an overseas vendor. The matter was decided in favour of the Company and the demand was cancelled by Commissioner of Income Tax (Appeals) ("CIT (Appeals)"). However, the Income Tax Department filed an appeal before Income Tax Appellate Tribunal ('ITAT') against the order of CIT (Appeals). During the financial year 2025-26 the same has been allowed in favour of the Company. Keeping in view that the stipulated period for filing of appeal by the Income Tax department against the said order of the Hon'ble ITAT is not yet over, the management has decided to continue to show the amount as a contingent liability.
ii) A search operation was conducted by the Income Tax Department in the premises of the Company in January 2012 and hence the Company re-filed the income tax returns for the Assessment Year 2006-07 to 2012-13. During the year ended March 31,2015, the Income Tax Department completed the assessment of the said years, disallowed certain expenses and issued demand of ?3,294.90 million (including interest) on various grounds. The Company preferred appeals before the CIT (Appeals) against the orders of the Income Tax Department. The appeals were decided in favour of the Company and the demand was cancelled. However, CIT (Appeals) made certain disallowances with respect to Assessment Year
2010- 11 and 2011-12 against which the Company filed appeals before the (ITAT). The Income Tax Department also filed appeal before ITAT against the orders of CIT (Appeals). During the financial year 2025-26, the Hon'ble ITAT has, vide its consolidated Order dated February 27, 2026 (a) dismissed all seven appeals filed by the Income Tax Department against the orders of the CIT (Appeals) for Assessment Years 2006-07 to 2012-13; (b) allowed both appeals filed by the Company against the CIT (Appeals) orders dated July 27, 2015, for Assessment Years 2010-11 and
2011- 12; and quashed the underlying assessment orders passed by the Assessing Officer / DCIT for Assessment Years 2006-07 to 2012-13, thereby providing complete relief to the Company. Keeping in view that the stipulated period for filing of appeal by the Income Tax Department against the said order of the Hon'ble ITAT is not yet over, the management has decided to continue to show this amount as a contingent liability.
iii) The Income Tax Department had raised a demand of ?33.69 million in respect of Assessment Year 2016-17 based on transfer pricing order passed by Dispute Resolution Panel. The alleged demand was raised on purchase of certain goods by the Company from its associated enterprise wherein, according to Income Tax Department, arms' length price adjustment was warranted. The Company filed appeal before ITAT against the order passed by the Income Tax Department. During financial year 2023-24, the said appeal has been decided in favour of the Company. Further, the department has filed an appeal before the Hon'ble Delhi High court, against the order of the Hon'ble ITAT. Based on legal advice, the Company believes that it has merits in this case, hence no provision is required.
iv) The Income Tax Department has levied a penalty of ?93.88 million in respect of Assessment Years 2017-18, 2020-21 & 2021-22 on account of alleged under reporting of income in assessment orders passed for the said years. The Company filed an appeal before CIT (Appeals) against the order passed by the Income Tax Department but the same was dismissed by the CIT (Appeals). The Company has filed an appeal before the Hon'ble ITAT against the order passed by the CIT (Appeals). Based on legal advice, the Company believes that it has merits in these cases, hence no provision is required.
v) The Income Tax Department had raised a demand of ?2,620.80 million in respect of Assessment Year 2020-21. The alleged demand was raised due to wrong addition of contingent liability not provided for, set-off of business losses not allowed and increase in other income due to set¬ off of business losses not allowed. The Ccompany filed an appeal before CIT (Appeals) and rectification application before assessing officer against the order passed by the Income Tax Department. During the financial year 2023-24, while the said appeal was under consideration, the assessing officer has passed rectification order in favour of the Company and reduced the said tax demand to ?91.63 million. The Company believes that it has merits in this case, hence no provision is required.
vi) The Income Tax Department has raised a demand of ?0.86 million in respect of Assessment Year 2018-19 on the ground of alleged non-
deduction of withholding tax on certain foreign remittances made by the Company. The Company has filed an appeal before CIT (Appeals) against the order passed by the Income Tax Department and the same was dismissed by the CIT (Appeals). The Company has filed an appeal before the Hon'ble ITAT against the order passed by the CIT (Appeals). Based on legal advice, the Company believes that it has merits in this case, hence no provision is required.
vii) Service tax and Excise & Custom duty litigations with respect to disallowance of input tax credit, rebate claim and levy of service tax are pending with various authorities. The Company believes that it has merit in these cases and hence no provision is required.
viii) The Company had manufactured and offered supply of certain vaccines which were manufactured against the confirmed order received from the Ministry of Health and Family Welfare ("MOHFW"), Govt. of India. Some quantities of vaccines were supplied during December 2011, the balance could not be supplied in view of disputes with respect to delivery dates and in the meantime the stock of such vaccines amounting to ?74.10 million expired. Further, the Company also received an advance market commitment ("AMC") amounting to ?100.00 million towards against these vaccines. The refund of the advance so received (after adjusting the amount receivable against the vaccines already supplied) was demanded back by MOHFW along with interest on account of non-supply of balance quantities of vaccines. In view of above disputes, the Company obtained a stay order from the Hon'ble Delhi High Court against recovery of said amount, till the disputes are finally resolved through arbitration. The arbitration award was pronounced in favour of the Company on March 14, 2019, vide which MOHFW was directed to pay the applicable amount for vaccine supplied / offered for supply along with interest. MOHFW filed an appeal before Hon'ble Delhi High Court raising certain objections against the award, which was dismissed by the Hon'ble Court. MOHFW filed an appeal against such order before the Division Bench of the Hon'ble Delhi High Court which was also rejected. MOHFW has filed a Special Leave Petition against such order before the Hon'ble Supreme Court of India. The same is currently pending before Hon'ble Supreme Court of India. The Company's application for execution of award is also currently pending before the Hon'ble Delhi High Court. The Company believes that it has merits in this case and the outcome of this matter will not have any material adverse impact on the financial position of the Company.
ix) In March 2024, the Company received summons from Asst. Commissioner of State Tax ("ACST”), Mumbai to enquire if the Company had paid GST on sale of the leasehold land and building at Navi Mumbai in March 2022. The Company's officials attended the proceedings and clarified that the GST was not applicable as the said transaction was covered under Schedule III to CGST / MGST Act. However, following persistent follow-up by the GST authorities, the Company deposited an amount of ?31.42 million under protest. The Company filed a writ petition before the Hon'ble High Court of Judicature at Bombay against the said proceedings. The Hon'ble High Court has set aside the demand order on January 22, 2025 and the matter was remanded back to the ACST, Mumbai for a fresh adjudication on the show cause notice. The Hon'ble High Court also directed the ACST, Mumbai to take into consideration and deal with the recent decision of the Gujarat High Court on a similar issue whilst rendering its findings on the show cause notice. Subsequently, ACST, Mumbai issued a fresh demand order of ?70.34 million (including interest and penalty) after adjusting ?31.42 million deposited under protest. The Company has again filed a writ petition before the Hon'ble High Court. The Hon'ble High Court has passed interim order stating that no recovery proceedings shall be initiated against the Company and the final order is yet to be passed. The Company believes that the Company has merits in its case and hence the Company has not made any provision in respect of this matter.
x) In December 2023, the Company received a demand order from State Tax Officer, Kerala raising demand of ?1.75 million (including penalty and applicable interest) for financial year 2017-18 rejecting the Company's claim for input tax credit on account of non-submission of relevant documents. The Company has filed an appeal on February 02, 2024 before the Appellate Authority which is pending. The Company believes that it has merit in this case and hence no provision is required.
xi) In February 2025, the Company received a demand order from Superintendent, Central Goods & Services Tax, Derabassi-I, Punjab raising demand of ?0.33 million (including penalty) and applicable interest for financial year 2020-21 on account of alleged excess claim of input credit w.r.t. import of goods. The Company has filed an appeal before the Appellate Authority against the aforesaid demand order on April 26, 2025. The Company believes that it has merit in this case and hence no provision is required.
xii) In September 2025, the Company has received show cause notice from Assistant Commissioner, Central GST (Audit), Ludhiana, Punjab for financial years 2019-20 to 2021-22 demanding GST of ?228.81 million and applicable interest on corporate guarantee of ?8,640.00 million provided by the Company in favour of its WOS Panacea Biotec Pharma Limited. The Company has filed a Writ Petition before the Hon'ble Punjab & Haryana High Court. The Hon'ble High Court has, vide its order dated January 1,2026, held that no coercive action be taken against the Company in case final assessment order is passed or a demand is raised. The Additional Commissioner, CGST Sub-Commissionerate, Mohali has issued a demand order dated March 30, 2026 confirming the aforesaid demand. The Company has filed an appeal against the said demand order before the Appellate Authority. The Company believes that the Company has merit in its case and hence the Company has not made any provision in respect of this matter.
xiii) In December 2025, the Company has received a demand order from Commercial Tax Officer, Tamil Nadu raising a demand of ?0.51 million (including penalty and interest) for financial year 2021-22 on account of alleged short payment of tax liability. The Company has filed an appeal against the order before the Appellate Authority on March 25, 2026. The Company believes that it has merit in this case and hence no provision is required.
xiv) With respect to the 4 old labour cases pending before the Presiding Officer, Industrial Tribunal, Mohali in respect of manufacturing facility of the Company at Lalru, Punjab, during financial year 2024-25, the Company initiated settlement process and recognised an amount of ?42.80 million as the compensation payable in respect of these cases, out of which ?22.51million has been paid as on March 31, 2026 (March 31, 2025: ?18.51 million) and the balance amount has been included as a liability in the financial statements. The Company has received 4 awards dated March 19, 2026, whereby the Tribunal has, inter-alia, set aside transfer of 23 workmen and granted relief of full back wages from the date of transfer; awarded reasonable wage revision for the workmen; and awarded reinstatement of the workers (other than those who have settled the dispute) with 50% back wages from the date of termination. The Company believes that it has merits in these cases. The Company is therefore filing appeals against the aforesaid awards before the Hon'ble Punjab and Haryana High Court, Chandigarh. Accordingly, the Company has not made any provisions in respect of these matters. In view of large number of other cases, it is impracticable to disclose each case.
38. Leases
Company as a lessee:
The Company does not have any long-term non cancellable leases during the current and previous financial year. As on April 1, 2019, leasehold land has been transferred to Right of Use ("RoU") asset. Refer note 2.1 for details.
Lease payments with respect to short term lease amounts to ?37.34 million (March 31,2025: ? 28.76 million).
Company as a lessor:
Operating leases
The Company has entered into operating leases on its investment property portfolio consisting of certain offices, guest house, warehouse, manufacturing buildings etc. These leases generally have terms of 11 months. All leases generally include a clause for upward revision of the rental charge by 5% on an annual basis according to prevailing market conditions. Rental income recognised by the Company from above said lease agreements is ?48.54 million (March 31,2025: ?45.42 million).
C. Defined contribution plans
The Company's contribution to state governed provident fund, employees' state insurance and labour welfare fund schemes are considered as defined contribution plans. The contribution for the current year is ?27.00 million (March 31,2025: ?25.51 million) and under the schemes is recognised as an expense, when an employee renders the related service. There are no other obligations of the Company, other than the contribution payable to the respective funds.
B.2 Financial assets and liabilities are measured at amortised cost. All the financial assets and liabilities valued at amortised cost form part of Level 3 of hierarchy table. Further, the carrying amounts of trade receivables, cash and cash equivalents, consignment debtors, interest accrued, other receivables, other bank balances, trade payables, employee payables and other current payables are considered to be the same as fair values, due to their short term nature. The fair value of all financial assets and financial liability, approximates the amortised cost due to their short term nature. They are classified as level 3 fair value in the fair value hierarchy due to the inclusion of unobservable inputs, including own credit risk. The fair value of loans to employees and security deposits approximates the carrying amount.
Risk management framework
The Company's activities expose it to market risk, liquidity risk and credit risk. The management has the overall responsibility for the establishment and oversight of the Company's risk management framework. This note explains the sources of risk which the entity is exposed to and how the entity manages the risk and the related impact in the financial statements.
A. Credit risk
Credit risk is the risk that a counter party fails to discharge its obligation to the Company. The Company's exposure to credit risk is influenced mainly by cash and cash equivalents, trade receivables and financial assets measured at amortised cost. The Company continuously monitors defaults of customers and other counter parties and incorporates this information into its credit risk controls.
A.1 Credit risk management
The Company assesses and manages credit risk based on internal credit rating system. Internal credit rating is performed for each class of financial instruments with different characteristics. The Company assigns the following credit ratings to each class of financial assets based on the assumptions, inputs and factors specific to the class of financial assets:
A: Low credit risk on financial reporting date B: Moderate credit risk C: High credit risk
Cash and cash equivalents and bank deposits: Credit risk related to cash and cash equivalents and bank deposits is managed by only accepting highly rated banks and diversifying bank deposits and accounts in different banks across the country.
Trade receivables: Credit risk related to trade receivables are mitigated by taking bank guarantees / letter of credit, from customers where credit risk is high. The Company closely monitors the credit-worthiness of the debtors through internal systems that are configured to define credit limits of customers, thereby limiting the credit risk to pre-calculated amounts. The Company assesses increase in credit risk on an ongoing basis for amounts receivable that become past due and default is considered to have occurred when amounts receivable become two year past due.
Other financial assets measured at amortised cost: Other financial assets measured at amortized cost includes security deposits and other Credit risk related to these other financial assets is managed by monitoring the recoverability of such amounts continuously.
The Company provides for expected credit losses on loans and advances other than trade receivables by assessing individual financial instruments for expectation of any credit losses. Since the Company deals with only high-rated banks and financial institutions, credit risk in respect of cash and cash equivalents, other bank balances and bank deposits is evaluated as very low. In respect of loans, comprising of security deposits, credit risk is considered low because the Company is in possession of the underlying asset. However, in respect of loans comprising loans to related parties, credit risk is evaluated on the basis of credit worthiness of those parties and loss allowance is measured as lifetime expected credit losses. In respect of other financial assets, credit risk is evaluated based on Company's knowledge of the credit worthiness of those parties and loss allowance is measured as lifetime expected credit losses. The Company does not have any expected loss based impairment recognised (except in case of loans to related parties) on such assets considering their low credit risk nature, though incurred loss provisions are disclosed under each sub-category of such financial assets.
A.3 Expected credit loss for trade receivables under simplified approach
The Company recognizes lifetime expected credit losses on trade receivables using a simplified approach, wherein the Company has defined percentage of provision by analysing historical trend of default relevant to each category of customer based on the criteria defined above and such provision percentage determined have been considered to recognise life time expected credit losses on trade receivables (other than those where default criteria are met). The Company has other trade receivables for ?172.30 million (March 31, 2025: ?184.26 million) against which it is carrying unsecured payables for corresponding amount for whose default criteria are not met and are not included in the below table.
Liquidity risk is the risk that the Company will encounter difficulty in meeting the obligations associated with its financial liabilities that are settled by delivering cash or another financial asset. The Company's approach to managing liquidity is to ensure as far as possible, that it will have sufficient liquidity to meet its liabilities when they are due. The Company manages its liquidity needs by carefully monitoring scheduled debt servicing payments for long-term financial liabilities as well as cash outflows due in day-to-day business. Long-term liquidity needs for a 180-day and a 360-day lookout period are identified monthly.
Management monitors rolling forecasts of the liquidity position and cash and cash equivalents on the basis of expected cash flows. The Company takes into account the liquidity of the market in which the entity operates.
B.1 Contractual maturities of financial liabilities
The tables below analyse the Company's financial liabilities based on their contractual maturities. The amounts disclosed in the table are the contractual undiscounted cash flows.
C. Market risk
(i) Interest rate risk
Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company's exposure to the risk of changes in market interest rate related primarily to the Company's non-current and current debt obligations financed with fixed interest rate. The Company always try to ensure minimum cash outlfows. The assumed movement in basis points for the interest rate sensitivity analysis is based on the currently observable market environment, showing a significantly higher volatility. Accordingly, the Company is not exposed to fluctuations in interest rate risk on borrowings.
The Company is exposed to foreign exchange risk arising from foreign currency transactions, primarily with respect to the United State Dollar (USD), Euro, Swiss Frank (CHF), Pound Sterling (GBP), Swedish Krona (SEK) and Singapore Dollar (SGD). Foreign exchange risk arises from recognised assets and liabilities denominated in a currency that is not the functional currency of the Company. The Company does not use any derivative instruments to manage its exposure. Also, the Company does not use forward contracts and swaps for speculative purposes.
The Company's capital management objectives are to ensure the Company's ability to continue as a going concern as well as to provide an adequate return to shareholders by pricing products and services commensurately with the level of risk.
The Company monitors capital on the basis of the carrying amount of equity plus its subordinated loan, less cash and cash equivalents as presented on the face of the statement of financial position recognised in other comprehensive income.
The Company manages its capital structure and makes adjustments to it in the light of changes in economic conditions and the risk characteristics of the underlying assets. In order to maintain or adjust the capital structure, the Company may adjust the amount of dividends paid to shareholders, return capital to shareholders or issue new shares. The Company is not subject to any externally imposed capital requirements. The amounts managed as capital by the Company are summarised as follows:
47. The Board of Directors of the Company and Panacea Biotec Pharma Limited ("PBPL") had in their respective meetings held on February 01, 2022, approved sale of PBPL's pharmaceutical formulations brands in India and Nepal including related trademarks, copyrights etc., including identified employees to Mankind Pharma Limited (the "Buyer”) for a consideration of ?18,720.00 million plus applicable taxes. The said transaction was approved by the shareholders of PBPL and the Company in their respective meetings held on February 23, 2022 and February 26, 2022, respectively. Subsequently, the Company and PBPL signed definitive agreements including the asset purchase agreement with the Buyer on February 28, 2022. Out of the total consideration, PBPL has recognised revenue of ?109.25 million (March 31, 2025: ?359.94 million) which is shown as an "Exceptional Item” in the Statement of Profit and Loss of PBPL and Consolidated Statement of Profit and Loss of the Group. The remaining consideration of ?101.80 million (March 31,2025: ?211.05 million) would be recognised as revenue in subsequent years and is shown as Contract Liability in the financial statements of PBPL and consolidated financial statements of the Group. Further, revenue of ?85.71 million (year ended March 31,2025: ? Nil) is also shown as "Exceptional item" pursuant to the settlement agreement dated July 09, 2025 executed with Apotex Inc. USA ("Apotex") to settle the ongoing dispute between Apotex and the Company & PBPL.
48. For the financial year ended March 31, 2026, the Company has incurred loss (including other comprehensive income) of ?287.60 million (year ended March 31, 2025: loss of ?151.74 million) and as on March 31, 2026, the retained earnings of the Company are negative to the extent of ?2,178.43 million (March 31,2025: ?1,890.83 million). The aforesaid conditions indicate the existence of uncertainty that may create doubt about the Company's ability to continue as a going concern. However, the retained earnings of the Group are positive to the extent of ?7,760.55 million (March 31,2025: ?7,799.13 million). The surplus funds remaining with the Group out of the sales of pharmaceutical formulations brands in India and Nepal in March 2022 have helped in strengthening the working capital position, setting up new facilities for enhancement of capacities for manufacturing of vaccines drug substance, scaling up Group's nutrition and pharmaceutical formulations business and pursuing other business opportunities. The Company has already received higher long-term awards from United Nations International Children's Fund (UNICEF) and Pan American Health Organisation (PAHO) for supply of pentavalent vaccine and awards from UNICEF for supply of bivalent oral polio vaccine. Based on these measures and continuous efforts to improve the business performance, the management has prepared the financial statements on going concern basis.
49. (a) In view of the Company's decision to make the structure of overseas subsidiaries more efficient and aligned to business objectives and to
save management and administrative expenses thereof, the Company has decided to wind up Panacea Biotec (International) SA ("PBS”) in due course. Accordingly, the Company has created provision for impairment on its investment in PBS. Owing to accumulated losses in PBS and its wholly owned subsidiary, Panacea Biotec Germany GmbH ("PBGG"), the Company has continued to maintain the provision for bad and doubtful advances in respect of the loans receivable and accrued interest from PBS and PBGG amounting to ?156.92 million and ?518.07 million, respectively, as on March 31, 2026 (March 31,2025: ?139.00 million and ?458.90 million, respectively).
(b) The Company has applied with the authorized dealer bank to seek permission from Reserve Bank of India for writing off an amount of ?585.16 million which was receivable from the Company's wholly owned subsidiary Rees Investments Ltd. ("Rees"), which was compulsorily liquidated and dissolved by the authorities of Guernsey on May 23, 2019. Pending such approval, the Company is continuing to maintain the provision for bad and doubtful advances of ?585.16 million (March 31,2025: ?585.16 million) in respect of the loan and accrued interest receivable from Rees.
50. Under the collaboration with the Human Vaccine Limited Liability Company, Russia ("HV”), an indirect wholly owned subsidiary of Joint Stock Company "Management Company of Russian Direct Investment Fund” for manufacture of Covid-19 vaccine using the technology to be provided by HV, the Company had received from HV an advance amount of US$ 7.00 million in November 2020, out of which ~US$ 6.58 million was used to meet the revenue expenses relating to Sputnik-V and Sputnik Light vaccine project. The Company believes that due to the failure on the part of HV to demonstrate & transfer the technology and certain other reasons beyond the Company's control, the complex process of technology transfer and manufacture of Sputnik-V vaccine could not be completed successfully and the Technology Transfer Agreement dated October 22, 2020 entered into between HV and the Company ("TTA”) for manufacturing of Covid-19 vaccine stood frustrated and accordingly both the parties stood automatically discharged from their obligations by operation of law. The Company is thus entitled to adjust the same against the advance received from HV. The Company has already conveyed its position to HV and has offered to refund the balance amount of US$ 0.42 million and provided relevant details / documents pertaining to the said expenses. On July 1, 2024, the Company received a copy of Request for Arbitration filed by HV with London Court of International Arbitration ("LCIA”) for initiating arbitration alleging that the Company has been in alleged breach of its obligations under the TTA and is thus liable to refund the advance payment of US$7.00 million plus interest thereon as may be awarded over the course of arbitration. Both parties have appointed the sole arbitrator in this matter. The Company is taking requisite steps to safeguard its interest and has filed its response along with witness statements and counter claims against HV. Further arbitration proceedings, including cross examinations etc. shall be completed in due course. Based on the Company's assessment, duly supported by legal advice, the Company believes that it will not be liable to pay back the amount adjusted towards wasted expenses and costs under dispute with HV and the outcome of this arbitration proceeding is not reasonably expected to have any material financial impact on the Company.
51. In August 2021, the Company had entered into a Licensing and Manufacture Agreement with HV, Generium JSC and Dr. Reddy's Laboratories Limited ("DRL"). As per the terms of the agreement, the Company was to undertake fill-and-finish activities of Sputnik-V vaccine using the ready-to-fill drug substance supplied by Generium and supply the Sputnik-V vaccine so produced to DRL. Pursuant to the said agreement, the Company received drug substance from Generium and produced ~1.96 million doses of Sputnik-V vaccine out of which DRL purchased ~0.86 million doses only and refused to purchase and pay for the remaining ~1.10 million doses. Because of breach of their respective obligations by DRL and Generium, the pending payment of ~US$ 7.41 million for the drug substance received from Generium could not be made. After several rounds of discussion among the parties to settle the dispute amicably, Generium has filed notice of arbitration with Singapore International Arbitration Centre (SIAC) for arbitration of dispute with respect to the said pending payment and interest thereon totalling ~US$ 8.90 million. The Company has also initiated a parallel arbitration proceeding regarding its claims against DRL, Generium and Human Vaccine and filed notice of arbitration with SIAC during the financial year 2023-24. At the Company's request, SIAC has clubbed both the arbitration proceedings together. The parties have appointed sole arbitrator. All the parties involved in the Arbitration have filed claims and counter claims against each other. The witness statements, cross examination and closing submissions have been completed and the arbitration award is now awaited. The Company has obtained legal opinion from its legal counsel who, have opined that (a) the Company has a reasonable defence against the claims brought by Generium, DRL and HV; and (b) the possibility of any such claim falling to the Company may be classified as low at this stage.
52. Additional regulatory information required by Schedule III under Companies Act 2013:
(i) The Company does not have any Benami Property, where any proceeding has been initiated or pending against the Company for holding any Benami property.
(ii) The Company does not have any transactions with stuck off companies.
(iii) The Company does not have any charges or satisfaction of charge which is yet to be registered with Registrar of Companies beyond the statutory period.
(iv) The Company has not traded or invested in Crypto Currency or Virtual Currency during the financial year.
(v) The Company has not advanced or loaned to, or invested funds in, any other person(s) or entity(ies), including foreign entities (Intermediaries)
with the understanding that the Intermediary shall:
- directly or indirectly lend to, or invest in, other persons or entities identified in any manner whatsoever by or on behalf of the Company (Ultimate Beneficiaries); or
- provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries.
(vi) The Company has not received any funds from any other person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Company shall:
- directly or indirectly lend to, or invest in, other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party or
- provide any guarantee, security or the like to or on behalf of the Funding Party.
(vii) The Company has not entered into any transaction which is not recorded into the books of accounts that has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961).
(viii) The Company has not been declared a 'Wilful Defaulter' by any bank or financial institution or government or any government authority.
(ix) The Company has complied with the number of layers prescribed under Section 2(87) of the Act read with the Companies (Restriction on Number of Layers) Rules, 2017.
(x) No scheme of arrangements has been approved by the Competent Authority in term of Sections 230 to 237 of the Companies Act, 2013, during the year and previous year.
(xi) The Company does not have any borrowings from banks or financial institutions against security of its current assets.
(xii) The title deeds of the immovable properties owned by the Company are held in the name of Company.
Notes:
a. no significant change (25% or more) in financial year 2025-26 in comparison to financial year 2024-25
b. due to increase in unsecured borrowings and losses
c. due to lower operating profits & increased interest cost
d. due to lower net operating profit
e. due to increased cost of goods sold
f. due to negative average working capital
54. On November 21, 2025, the Government of India notified provisions of the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020 and the Occupational Safety, Health and Working Conditions Code, 2020 ('Labour Codes') which consolidate 29 (twenty- nine) existing labour laws into a unified framework governing employee benefit during employment and post-employment. The Labour Codes, amongst other things, introduces changes including a uniform definition of wages. The incremental impact of these changes, assessed by the Company, on the basis of the information available, consistent with the guidance provided by the Institute of Chartered Accountants of India, has been accounted for accordingly. Once Central / State Rules are notified by the Government upon all the aspects of the Labour Codes, the Company shall evaluate additional impact, if any, on the measurement of employee benefits and would provide appropriate accounting effect.
55. In October 2023, the Company received notice from the International Court of Arbitration, Paris ("ICC") intimating commencement of an Arbitration proceeding pursuant to the request filed by Apotex Inc., claiming an amount of US$ 118.14 million towards outsized alleged losses plus interest thereon under the Collaboration Agreement dated May 09, 2014 entered into between Apotex Inc. and the Company. The said agreement was subsequently assigned and novated in favour of Panacea Biotec Pharma Limited ("PBPL") wholly owned subsidiary of the Company. The Company submitted its response to the notice of arbitration rebutting the claims raised by Apotex citing novation of the said agreement in favour of PBPL. Apotex subsequently filed request for joinder of PBPL in the said arbitration proceedings, raising the claim against the Company and PBPL aggregating to US$163.24 million, which was objected by the Company and PBPL. The management believed that the Company and / or PBPL is not in breach of its obligations and the claims filed by Apotex are frivolous, unsubstantiated, premised on fundamental factual misstatements and incorrect legal assumptions regarding the Collaboration
Agreement and contrary to the overwhelming facts and evidence. Both sides appointed their respective arbitrators, and these arbitrators nominated the third arbitrator as the chairman of the arbitration tribunal. PBPL also filed a request for arbitration before ICC with respect to dispute with Apotex raising a claim of US$ 9.90 million towards PBPL's share of profit from sale of authorized generic products sold by Apotex during financial year 2022-23 in USA under the terms of the said Collaboration Agreement and the settlement agreement signed among the Parties including the innovator company. ICC combined the two arbitrations proceedings and thereafter the initial arbitration proceedings were started. During financial year 2025-26, both the parties have executed a Settlement Agreement dated July 3, 2025 recording full and final settlement of the disputes forming part of the arbitration. Pursuant to the settlement Apotex has inter-alia, agreed to pay US$ 5.0 million in 2 tranches (US$ 2.5 million within 30 days and US$ 2.5 million upon receipt of final USFDA approval of the ANDA). The Arbitration Tribunal has made the Consent Award on September 12, 2025 in this regard.
56. The Ministry of Corporate Affairs (MCA) has prescribed a new requirement for companies under the proviso to Rule 3(1) of the Companies (Accounts) Rules, 2014 inserted by the Companies (Accounts) Amendment Rules, 2021 requiring companies, which uses accounting software for maintaining its books of account, shall use only such accounting software which has a feature of recording audit trail of each and every transaction, creating an edit log of each change made in the books of account along with the date when such changes were made and ensuring that the audit trail cannot be disabled.
Management has used an accounting software for maintaining its books of account which has a feature of recording audit trail (edit log) facility and the same has operated throughout the year for all relevant transactions recorded in the software, except that the audit trail feature was not enabled at the database level for accounting software to log any direct data changes, used for maintenance of all accounting records by the Company.
Further, the audit trail feature has not been tampered with during the year and the audit trail, to the extent maintained in the prior years, has been preserved by the Company as per the statutory requirements for the record retention.
57. In accordance with Ind AS 108, 'Operating Segments', the Company has disclosed the segment information in the consolidated financial statements. Accordingly, the segment information is given in the audited consolidated financial statements of the Group for the year ended March 31,2026.
58. 0.00 under "? in million” represents amount less than ?50,000 and 0.00 under units represents units less than 50,000. Further, the figures shown in the tables may not exactly add up due to rounding off. Previous year figures have been regrouped, reclassified wherever considered necessary. The impact of such reclassification/regrouping is not material to the financial statements.
59. There are no other subsequent events that occurred after reporting date.
|